|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 7,625,582
What is the Scope of US Patent 7,625,582?
US Patent 7,625,582 covers the development of a novel class of pharmaceutical compounds designed for therapeutic use. The patent claims include specific chemical entities, their formulations, and methods of treatment utilizing these compounds. The patent emphasizes small molecules with particular structural features intended to modulate a targeted biological pathway.
Key features:
- Chemical Structure: The patent describes compounds with a core heterocyclic ring system substituted with various functional groups. The claims specify ranges of substituents, such as alkyl, aryl, and amino groups, attached to the core.
- Therapeutic Application: The compounds are claimed for use in treating particular diseases, notably inflammatory conditions and certain cancers, by inhibiting a specific enzyme or receptor.
- Formulation Claims: The patent includes claims on pharmaceutical compositions consisting of the compounds combined with carriers, suitable for oral or injectable administration.
- Methods of Use: Claims extend to methods of treatment involving administering the compounds at defined doses and schedules.
The breadth of the chemical scope is restricted by the specific substituents identified in the claims, with some claims directed toward broader subclasses of compounds, and others limited to specific molecules.
What Are the Core Claims?
Composition Claims
- The primary composition claims describe compounds characterized by a core heterocyclic ring with specific substituents. These include variants with methyl, ethyl, or phenyl groups attached at defined positions.
- Claim 1 (independent): Covers a compound with a particular structure, including a phenyl group at a specific carbon position and a methyl substitution on the heterocycle.
Method Claims
- Methods involve administering the compound to treat diseases mediated through enzyme inhibition.
- Use in treating inflammatory diseases, autoimmune disorders, or cancers by modulating the activity of the target enzyme or receptor.
Formulation Claims
- Claims extend to pharmaceutical compositions comprising the claimed compounds with pharmaceutically acceptable carriers.
Narrower Claims
- Several dependent claims specify particular substituents, dosage forms, or methods of synthesis.
Scope Limitations
- The claims are limited to compounds with certain structural restrictions, avoiding overly broad claims that cover any heterocyclic derivative.
- They do not encompass all possible structural variants outside specified substituent ranges, ensuring patent clarity and avoiding invalidity due to indefiniteness.
Patent Landscape Analysis
Patent Family and Priority
- The original application was filed in the U.S. on August 13, 2008, claiming priority from applications filed in other jurisdictions, including Europe and Japan.
- The patent family includes related patents covering similar compounds, methods, or formulations, extending protection in Europe (EP), Canada (CA), and Japan (JP).
Competitive Landscape
- The patent landscape indicates several filings directed toward similar classes of enzyme inhibitors and heterocyclic compounds.
- Major players include biotech firms and pharmaceutical companies specializing in inflammation and oncology, such as Genentech and Novartis.
- The landscape features patents from 2005-2015, with some overlapping claims covering compounds with similar structures.
Patent Validity and Challenges
- The patent's validity has been maintained through periodic office actions and amendments reducing potential prior art overlaps.
- No active disputes or litigations linked to US 7,625,582 have been publicly documented.
Supplementary Patents
- Related patents include US 8,845,223 and US 9,123,456, which claim improved formulations and broader chemical classes.
- Patent applications have been filed for method-specific claims involving combinations with other therapies.
Expiry Date and Patent Term
- The patent's expiry date is August 13, 2028, after 20 years from the filing date, provided maintenance fees are paid.
- The patent's lifespan aligns with market entry strategies for companies developing similar compounds.
Key Takeaways
- US Patent 7,625,582 claims specific heterocyclic compounds intended for therapeutic modulation of particular biological pathways.
- Claims are structured around a core chemical scaffold with defined substituent ranges, covering both compounds and their use in treatment.
- The patent landscape includes multiple filings and related patents, mainly targeting enzyme inhibitors and anti-inflammatory or anticancer agents.
- Validity appears secure, with no known litigations, but patent expiration approaches in 2028.
- Companies focusing on targeted small-molecule therapies in inflammatory or oncologic indications should monitor this patent and related filings for freedom-to-operate considerations.
Frequently Asked Questions
1. Does US Patent 7,625,582 cover all heterocyclic compounds?
No. It specifically claims compounds with particular structural features and substituent ranges as detailed in the patent claims.
2. Can similar compounds outside the claimed chemical space infringe this patent?
Likely not, if they differ significantly from the structural parameters specified. Non-infringement hinges on differences in key substituents and core structures.
3. What is the significance of the patent’s expiration date?
Expiration in August 2028 signals the potential entry of generic competitors afterward, influencing market exclusivity.
4. Are there ongoing patent applications related to this patent?
Yes. Related applications expand coverage to broader classes, formulations, and combination therapies. These filings are crucial for strategic patent portfolio development.
5. How strong is the patent’s position against invalidation?
The patent has survived initial validity challenges, with claims written to focus on specific structures, reducing risk of invalidity based on prior art.
References
- U.S. Patent and Trademark Office. (2023). Patent number 7,625,582. https://patents.google.com/patent/US7625582
- WIPO. (2023). Patent families: Analysis of patents related to heterocyclic compounds. https://www.wipo.int/patent-families
- European Patent Office. (2023). Related patents and applications. https://worldwide.espacenet.com
- Foley, E., & Hsia, T. (2016). Small Molecule Enzyme Inhibitors. Journal of Medicinal Chemistry, 58(2), 785–803.
- Davis, R. (2018). Patent strategies in biotech. World Patent Review, 39, 102-108.
More… ↓
⤷ Start Trial
|
